Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol DOI Open Access
José Manuel Quesada‐Gómez, José López‐Miranda, Marta Entrenas Castillo

et al.

Nutrients, Journal Year: 2022, Volume and Issue: 14(13), P. 2716 - 2716

Published: June 29, 2022

The COVID-19 pandemic is the greatest challenge facing modern medicine and public health systems. viral evolution of SARS-CoV-2, with emergence new variants in-creased infectious potential, a cause for concern. In addition, vaccination coverage remains in-sufficient worldwide. Therefore, there need to develop therapeutic options, and/or optimize repositioning drugs approved other indications COVID-19. This may include use calcifediol, prohormone vitamin D endocrine system (VDES) as it have potential useful effects treatment We review aspects associating VDES calcifediol in VDES/VDR stimulation enhance innate antiviral effector mechanisms, facilitating induction antimicrobial peptides/autophagy, critical modulatory role subsequent host reactive hyperinflammatory phase during COVID-19: By decreasing cytokine/chemokine storm, regulating renin–angiotensin–bradykinin (RAAS), modulating neutrophil activity maintaining integrity pulmonary epithelial barrier, stimulating repair, directly indirectly increased coagulability prothrombotic tendency associated severe its complications. Available evidence suggests that stimulation, while optimal serum 25OHD status, patients SARS-CoV-2 infection significantly reduce risk acute respiratory distress syndrome (ARDS) COVID-19, possible beneficial on mechanical ventilation intensive care unit (ICU) admission, well deaths course disease. pharmacokinetic functional characteristics give superiority rapidly optimizing levels A pilot study several observational intervention studies using high doses (0.532 mg day 1 0.266 days 3, 7, 14, 21, 28) dramatically decreased ICU admission mortality rate. We, therefore, propose at described rapid correction deficiency all early stages association, if necessary, oral agents.

Language: Английский

The role of vitamin D in reducing SARS-CoV-2 infection: An update DOI Open Access
Mohammad Shah Alam, Daniel M. Czajkowsky, MA Islam

et al.

International Immunopharmacology, Journal Year: 2021, Volume and Issue: 97, P. 107686 - 107686

Published: April 19, 2021

Language: Английский

Citations

44
A Literature Review of the Potential Impact of Medication on Vitamin D Status DOI
Michael Wakeman

Risk Management and Healthcare Policy, Journal Year: 2021, Volume and Issue: Volume 14, P. 3357 - 3381

Published: Aug. 1, 2021

Abstract: In recent years, there has been a significant increase in media coverage of the putative actions vitamin D as well possible health benefits that supplementation might deliver. However, potential effect medications may have on status is rarely taken into consideration. This literature review was undertaken to assess degree which be affected by medication. Electronic databases were searched identify relating this subject, and study characteristics conclusions scrutinized for evidence associations. The following groups drugs identified one or more studies affect some way: anti-epileptics, laxatives, metformin, loop diuretics, angiotensin-converting enzyme inhibitors, thiazide statins, calcium channel blockers, antagonists K, platelet aggregation digoxin, potassium-sparing benzodiazepines, antidepressants, proton pump histamine H 2 -receptor antagonists, bile acid sequestrants, corticosteroids, antimicrobials, sulphonamides urea derivatives, lipase hydroxychloroquine, highly active antiretroviral agents, certain chemotherapeutic agents. Given quality data heterogeneous, newer, robustly designed are required better define likely interactions between medications. especially so cytochrome P450 3A4 (CYP3A4)-metabolized Nevertheless, suggests providers care ought alert depletions induced medications, elderly people exposed multiple-drug therapy, provide if required. Keywords: ergocalciferol, cholecalciferol, D, medication interactions, drug

Language: Английский

Citations

41
Complementary and alternative medicine (CAM) interventions for COVID-19: An overview of systematic reviews DOI
Sae-Rom Jeon, Jung Won Kang, Lin Ang

et al.

Integrative Medicine Research, Journal Year: 2022, Volume and Issue: 11(3), P. 100842 - 100842

Published: March 13, 2022

Language: Английский

Citations

37
Consensus and Controversial Aspects of Vitamin D and COVID-19 DOI Open Access
John P. Bilezikian, Neil Binkley,

Hector F De Luca

et al.

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2022, Volume and Issue: 108(5), P. 1034 - 1042

Published: Dec. 8, 2022

Abstract Objective This work aims to review and discuss controversial topics in the field of vitamin D, SARS-CoV-2 infection, COVID-19. Methods The International Conferences “Controversies Vitamin D” are a series workshops that started 2017 featuring international experts leaders D research clinical practice. fifth annual conference was held Stresa, Italy, September 15 18, 2021. Evidence Before event, participants reviewed available studies on their assigned topic, drafted related abstract, presented findings at time conference. Relevant literature became since also discussed within panel updated accordingly. Consensus abstracts had been merged prepare preliminary document. After presentations, in-depth discussions open sessions led consensus. document subsequently modified according up-to-date inclusion. Conclusions There is quite consistent evidence for an association between low 25 OH (25(OH)D) levels poor COVID-19 outcomes, despite heterogeneous publications variable quality. However, status patients might reflect reverse causality. supplementation have positive role prevention. supporting beneficial effect treatment decreasing risk complications conflicting. Conclusive statements regarding this context await high-quality, randomized controlled trials.

Language: Английский

Citations

34
Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol DOI Open Access
José Manuel Quesada‐Gómez, José López‐Miranda, Marta Entrenas Castillo

et al.

Nutrients, Journal Year: 2022, Volume and Issue: 14(13), P. 2716 - 2716

Published: June 29, 2022

The COVID-19 pandemic is the greatest challenge facing modern medicine and public health systems. viral evolution of SARS-CoV-2, with emergence new variants in-creased infectious potential, a cause for concern. In addition, vaccination coverage remains in-sufficient worldwide. Therefore, there need to develop therapeutic options, and/or optimize repositioning drugs approved other indications COVID-19. This may include use calcifediol, prohormone vitamin D endocrine system (VDES) as it have potential useful effects treatment We review aspects associating VDES calcifediol in VDES/VDR stimulation enhance innate antiviral effector mechanisms, facilitating induction antimicrobial peptides/autophagy, critical modulatory role subsequent host reactive hyperinflammatory phase during COVID-19: By decreasing cytokine/chemokine storm, regulating renin–angiotensin–bradykinin (RAAS), modulating neutrophil activity maintaining integrity pulmonary epithelial barrier, stimulating repair, directly indirectly increased coagulability prothrombotic tendency associated severe its complications. Available evidence suggests that stimulation, while optimal serum 25OHD status, patients SARS-CoV-2 infection significantly reduce risk acute respiratory distress syndrome (ARDS) COVID-19, possible beneficial on mechanical ventilation intensive care unit (ICU) admission, well deaths course disease. pharmacokinetic functional characteristics give superiority rapidly optimizing levels A pilot study several observational intervention studies using high doses (0.532 mg day 1 0.266 days 3, 7, 14, 21, 28) dramatically decreased ICU admission mortality rate. We, therefore, propose at described rapid correction deficiency all early stages association, if necessary, oral agents.

Language: Английский

Citations

29